Clinical trials: Postprandial Glycemic Control
Type 1 Diabetes
New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy
Achieving near-normoglycemia has been established as the main objective for most patients with type 1 diabetes (T1DM). However, insulin dosing is an empirical process and its success is highly dependent on the patients' and…
- Trial name
- NCT01550809
- Testing
- iBolus, tBolus (traditional bolus)
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Postprandial Hyperglycemia
Comparison of the Postprandial Glycemic and Insulinemic Response After a Fibersym Containing Cookie With a Control
Fibersym® is a RS4-type resistant modified wheat starch in which over 85% of the total starch is resistant starch as measured by AOAC method 991.43.
- Trial name
- NCT04820322
- Testing
- Fibersym, Control cookie
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- MGP Ingredients, Inc.
Type 2 Diabetes Treated With Insulin
Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
Hyperglycemia affects 30-40% of hospitalized patients. Despite the fact that basal/bolus insulin therapy has been demonstrated to improve glycemic control and clinical outcomes in patients, achieving good glucose control remains…
- Trial name
- In-FI (NCT04460326)
- Testing
- Insulin glargine, NovoLog, Insulin Fiasp
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Boston Medical Center
Type 1 Diabetes Mellitus
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
This study is designed to investigate the clinical efficacy and safety of pramlintide co-administered as a fixed-dose ratio with basal-bolus SC insulin, delivered simultaneously via 2 separate pumps, in subjects with type 1…
- Trial name
- NCT02500979
- Testing
- Pramlintide acetate, Lispro insulin U-100, Regular insulin U-100
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca